Krystal Biotech PE ratio KRYS

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Oct 23, 2026: 39.0×
2-year median: 42.7×
Against its 2-year history: 33rd; percentile: 0 is its lowest day, 100 its highest
2-year range: 28.2× to 114×
Peer median: 29.3×

Krystal Biotech's PE ratio is 39.0× as of Oct 23, 2026: a share price of $311.50 against $7.98 of earnings per share over the last twelve months.

That is below its 2-year median of 42.7×, lower than on 67% of days in the last 2 years.

Over that time it ranged from 28.2× in Aug 2025 to 114× in Jul 2024.

The median for 10 biotech stocks of a similar size is 29.3×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	39.0×	35.8×	50.1×
2025	37.8×	28.2×	90.2×
2024	90.0×	48.1×	114×

Against its peers

Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.

Company	PE ratio
KRYSKrystal Biotech	39.0×
RGENRepligen	242×
TECHBIO-TECHNE	63.1×
HALOHalozyme Therapeutics	37.5×
NBIXNeurocrine Biosciences	20.9×
EXELExelixis	20.3×
INCYIncyte	14.7×
UTHRUnited Therapeutics	21.0×
ALNYAlnylam Pharmaceuticals	37.8×
ADMAAdma Biologics	15.3×
VCELVericel	92.5×
Peer median	29.3×

Where Krystal Biotech ranks

#12of 16Biotech stocks with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Krystal Biotech

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.